A Phase 1 interventional study of TAK-117 and Lansoprazole in Neoplasm, Advanced or Metastatic, sponsored by Millennium Pharmaceuticals, Inc.. Completed. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-01-08.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the relative bioavailability of a new tablet formulation of TAK-117 (new clinical trial material [NTM]) compared to the TAK-117 Process B capsules (current clinical trial material [CTM]) (Part 1), to assess the effects of food on the oral bioavailability and pharmacokinetics (PK) of TAK-117 (Part 2), and to assess the effects of gastric pH-modifying agent on the PK of TAK-117 in healthy participants (Part 3).
The drug being tested in this study is called TAK-117. TAK-117 is being tested to treat people who have advanced solid tumors. This study will look at the PK and relative bioavailability of new tablet formulation of TAK-117 as compare to current capsule formulation in Part 1. In Part 2 and Part 3, interaction of TAK-117 with food and a gastric pH modifying agent will be evaluated respectively in healthy participants, and will commence only after the completion of Part 1.
The study will enroll approximately 54 participants. In Part 1, participants will be randomly assigned (by chance, like flipping a coin) to 1 of the 2 crossover sequences:
Part 2 and Part 3 will be evaluated only on the new tablet formulation of TAK-117 at the dose determined in Part 1. In Part 2, participants will be randomly assigned to receive a single dose of TAK-117 in the fasted state followed by TAK-117 with standard high-fat breakfast in Sequence A or vice-versa in Sequence B. In Part 3, participants will receive a single dose of TAK-117 on Day 1 followed by lansoprazole 30 mg on Day 10 for 6 days and then second dose of TAK-117 on Day 15. Blood samples will be collected at predose and up to 72 hours postdose at prespecified time points on Days 1 and 15. Urine samples will be collected predose, 0 to 12 hours, and 12 to 24 hours postdose in Part 1 only.
This single center trial will be conducted in the United States. The overall time to participate in this study is approximately 45 days. Participants will make 2 visits to the clinic in each part, during which they will remain confined to the clinic for a 4 to 10 day period for drug dosing and other study procedures. Participants will also complete a final visit 30 to 33 days after their last dose of study drug for a follow-up assessment (Day 45).
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 54 is close to the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TAK-117900 milligram (mg), capsules, orally, once on Day 1, followed by 2 weeks of washout, followed by TAK-117 900 mg, tablets, orally, once on Day 15.
Drug: TAK-117
TAK-117 900 mg tablets, orally, once on Day 1, followed by 2 weeks of washout, followed by TAK-117 900 mg, capsules, orally, once on Day 15.
Drug: TAK-117
TAK-117 at the dose determined in Part 1, tablets, in fasted condition, orally, once on Day 1, followed by 2 weeks of washout, followed by TAK-117 at the dose determined in Part 1, tablets, with a standard high-fat meal, orally, once on Day 15.
Drug: TAK-117
TAK-117 at the dose determined in Part 1, tablets, with a standard high-fat meal, orally, once on Day 1, followed by 2 weeks of washout, followed by TAK-117 at the dose determined in Part 1, tablets, in fasted condition, orally, once on Day 15.
Drug: TAK-117
TAK-117 at the dose determined in Part 1, tablets, orally, once on Day 1, followed by lansoprazole 30 mg, tablets or capsules, once daily from Day 10 to Day 15, followed by TAK-117 at the dose determined in Part 1, tablets, orally, once on Day 15.
Drug: Lansoprazole · Drug: TAK-117
Cmax: Maximum Observed Plasma Concentration for TAK-117
Time frame: Part 1 and 2: Day 1 or 15 pre-dose and at multiple time points (up to 72 hours) post-dose; Part 3: Day 1 (TAK-117) and Day 15 (TAK-117 + Lansoprazole) pre-dose and at multiple time points (up to 72 hours) post-dose
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-117
Time frame: Part 1 and 2: Day 1 or 15 pre-dose and at multiple time points (up to 72 hours) post-dose; Part 3: Day 1 (TAK-117) and Day 15 (TAK-117 + Lansoprazole) pre-dose and at multiple time points (up to 72 hours) post-dose
AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-117
Time frame: Part 1 and 2: Day 1 or 15 pre-dose and at multiple time points (up to 72 hours) post-dose; Part 3: Day 1 (TAK-117) and Day 15 (TAK-117 + Lansoprazole) pre-dose and at multiple time points (up to 72 hours) post-dose
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-117
Time frame: Part 1 and 2: Day 1 or 15 pre-dose and at multiple time points (up to 72 hours) post-dose; Part 3: Day 1 (TAK-117) and Day 15 (TAK-117 + Lansoprazole) pre-dose and at multiple time points (up to 72 hours) post-dose
Part 1: Renal Clearance (CLr) of TAK-117
Time frame: Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose
Participants took part in the study at 1 investigative site in the United States from 08 January 2016 to 22 July 2016.
| Milestone | Part-1: TAK-117 900 mg Capsules + TAK-117 900 mg Tablets | Part-1: TAK-117 900 mg Tablets + TAK-117 900 mg Capsules | Part-2: TAK-117 600 mg Fasted + TAK-117 600 mg Fed | Part-2: TAK-117 600 mg Fed + TAK-117 600 mg Fasted | Part-3: TAK-117 900 mg + Lansoprazole 30 mg |
|---|---|---|---|---|---|
| Started | 11 | 9 | 8 | 10 | 16 |
| Completed | 9 | 8 | 7 | 9 | 16 |
| Not completed | 2 | 1 | 1 | 1 | 0 |
| Withdrew: Other | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 2 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 |
| Milestone | Part-1: TAK-117 900 mg Capsules + TAK-117 900 mg Tablets | Part-1: TAK-117 900 mg Tablets + TAK-117 900 mg Capsules | Part-2: TAK-117 600 mg Fasted + TAK-117 600 mg Fed | Part-2: TAK-117 600 mg Fed + TAK-117 600 mg Fasted | Part-3: TAK-117 900 mg + Lansoprazole 30 mg |
|---|---|---|---|---|---|
| Started | 9 | 8 | 7 | 9 | 0 |
| Completed | 9 | 8 | 7 | 9 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part-1: TAK-117 900 mg Capsules + TAK-117 900 mg Tablets | Part-1: TAK-117 900 mg Tablets + TAK-117 900 mg Capsules | Part-2: TAK-117 600 mg Fasted + TAK-117 600 mg Fed | Part-2: TAK-117 600 mg Fed + TAK-117 600 mg Fasted | Part-3: TAK-117 900 mg + Lansoprazole 30 mg |
|---|---|---|---|---|---|
| Started | 9 | 8 | 7 | 9 | 0 |
| Completed | 9 | 8 | 7 | 9 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| nanogram per milliliter (ng/mL) | Part-1: TAK-117 900 mg Capsules (9*100 mg Capsules) | Part-1: TAK-117 900 mg Tablets (3*300 mg Tablets) | Part-2: TAK-117 600 mg Fasted (2*300 mg Tablets) | Part-2: TAK-117 600 mg Fed (2*300 mg Tablets) | Part-3: TAK-117 900 mg (3*300 mg Tablets) | Part-3: TAK-117 900 mg (3*300 mg Tablets) + Lansoprazole 30 mg |
|---|---|---|---|---|---|---|
| Cmax: Maximum Observed Plasma Concentration for TAK-117 | 4632.992 ± 71 | 6225.347 ± 53 | 6455.111 ± 48 | 7847.591 ± 24 | 5859.156 ± 58 | 190.172 ± 144 |
| hours | Part-1: TAK-117 900 mg Capsules (9*100 mg Capsules) | Part-1: TAK-117 900 mg Tablets (3*300 mg Tablets) | Part-2: TAK-117 600 mg Fasted (2*300 mg Tablets) | Part-2: TAK-117 600 mg Fed (2*300 mg Tablets) | Part-3: TAK-117 900 mg (3*300 mg Tablets) | Part-3: TAK-117 900 mg (3*300 mg Tablets) + Lansoprazole 30 mg |
|---|---|---|---|---|---|---|
| Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-117 | 2.067 (1.00 to 6.00) | 3.000 (0.500 to 6.00) | 3.000 (2.00 to 6.07) | 6.033 (4.00 to 8.03) | 3.000 (1.00 to 6.00) | 3.517 (1.00 to 6.00) |
| nanogram*hour per milliliter (ng*hr/mL) | Part-1: TAK-117 900 mg Capsules (9*100 mg Capsules) | Part-1: TAK-117 900 mg Tablets (3*300 mg Tablets) | Part-2: TAK-117 600 mg Fasted (2*300 mg Tablets) | Part-2: TAK-117 600 mg Fed (2*300 mg Tablets) | Part-3: TAK-117 900 mg (3*300 mg Tablets) | Part-3: TAK-117 900 mg (3*300 mg Tablets) + Lansoprazole 30 mg |
|---|---|---|---|---|---|---|
| AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-117 | 45727.280 ± 94 | 66015.952 ± 91 | 71442.968 ± 67 | 127143.511 ± 39 | 63165.064 ± 91 | 1018.650 ± 129 |
| ng*hr/mL | Part-1: TAK-117 900 mg Capsules (9*100 mg Capsules) | Part-1: TAK-117 900 mg Tablets (3*300 mg Tablets) | Part-2: TAK-117 600 mg Fasted (2*300 mg Tablets) | Part-2: TAK-117 600 mg Fed (2*300 mg Tablets) | Part-3: TAK-117 900 mg (3*300 mg Tablets) | Part-3: TAK-117 900 mg (3*300 mg Tablets) + Lansoprazole 30 mg |
|---|---|---|---|---|---|---|
| AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-117 | 64165.340 ± 77 | 96293.083 ± 77 | 81595.634 ± 61 | 128336.896 ± 39 | 85782.122 ± 85 | 6547.254 ± 66 |
| liter per hour (L/hr) | Part-1: TAK-117 900 mg Capsules (9*100 mg Capsules) | Part-1: TAK-117 900 mg Tablets (3*300 mg Tablets) |
|---|---|---|
| Part 1: Renal Clearance (CLr) of TAK-117 | 0.314 ± 0.1179 | 0.311 ± 0.1304 |
Collected over Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days (Day 46) after the last dose of study drug. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part-1: TAK-117 900 mg Capsules | — | 0/19 (0%) | 3/19 (15.8%) |
| Part-1: TAK-117 900 mg Tablets | — | 0/18 (0%) | 5/18 (27.8%) |
| Part-2: TAK-117 600 mg Fasted | — | 0/17 (0%) | 8/17 (47.1%) |
| Part-2: TAK-117 600 mg Fed | — | 0/17 (0%) | 4/17 (23.5%) |
| Part-3: TAK-117 900 mg | — | 0/16 (0%) | 6/16 (37.5%) |
| Part-3: Lansoprazole 30 mg | — | 0/16 (0%) | 1/16 (6.3%) |
| Part 3: Lansoprazole 30 mg + TAK-117 900 mg | — | 0/16 (0%) | 1/16 (6.3%) |
| Event | Part-1: TAK-117 900 mg Capsules | Part-1: TAK-117 900 mg Tablets | Part-2: TAK-117 600 mg Fasted | Part-2: TAK-117 600 mg Fed | Part-3: TAK-117 900 mg | Part-3: Lansoprazole 30 mg | Part 3: Lansoprazole 30 mg + TAK-117 900 mg |
|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 3/19 | 3/18 | 7/17 | 4/17 | 5/16 | 0/16 | 0/16 |
| VomitingGastrointestinal disorders | 3/19 | 2/18 | 1/17 | 1/17 | 0/16 | 0/16 | 0/16 |
| HeadacheNervous system disorders | 1/19 | 0/18 | 2/17 | 0/17 | 2/16 | 1/16 | 0/16 |
| DiarrhoeaGastrointestinal disorders | 0/19 | 0/18 | 1/17 | 0/17 | 1/16 | 0/16 | 0/16 |
| Abdominal painGastrointestinal disorders | 0/19 | 0/18 | 0/17 | 0/17 | 1/16 | 0/16 | 0/16 |
| Decreased appetiteMetabolism and nutrition disorders | 1/19 | 0/18 | 0/17 | 0/17 | 1/16 | 0/16 | 0/16 |
| DizzinessNervous system disorders | 1/19 | 0/18 | 1/17 | 0/17 | 1/16 | 0/16 | 0/16 |
| ParaesthesiaNervous system disorders | 0/19 | 0/18 | 0/17 | 0/17 | 0/16 | 0/16 | 1/16 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/19 | 0/18 | 0/17 | 0/17 | 0/16 | 1/16 | 0/16 |
| Dry throatRespiratory, thoracic and mediastinal disorders | 0/19 | 0/18 | 0/17 | 0/17 | 1/16 | 0/16 | 0/16 |
Safety analysis population included all the participants who received at least 1 dose of study drug.
| Age, Customized(participants) | Part-1: TAK-117 900 mg Capsules + TAK-117 900 mg Tablets | Part-1: TAK-117 900 mg Tablets + TAK-117 900 mg Capsules | Part-2: TAK-117 600 mg Fasted + TAK-117 600 mg Fed | Part-2: TAK-117 600 mg Fed + TAK-117 600 mg Fasted | Part-3: TAK-117 900 mg + Lansoprazole 30 mg | Total |
|---|---|---|---|---|---|---|
| 18-45 years | 11 ± 7.63 | 9 ± 7.79 | 8 ± 7.15 | 10 ± 6.13 | 16 ± 6.88 | 54 |
| Sex: Female, Male(Participants) | Part-1: TAK-117 900 mg Capsules + TAK-117 900 mg Tablets | Part-1: TAK-117 900 mg Tablets + TAK-117 900 mg Capsules | Part-2: TAK-117 600 mg Fasted + TAK-117 600 mg Fed | Part-2: TAK-117 600 mg Fed + TAK-117 600 mg Fasted | Part-3: TAK-117 900 mg + Lansoprazole 30 mg | Total |
|---|---|---|---|---|---|---|
| Female | 8 | 7 | 4 | 10 | 9 | 38 |
| Male | 3 | 2 | 4 | 0 | 7 | 16 |
| Ethnicity (NIH/OMB)(Participants) | Part-1: TAK-117 900 mg Capsules + TAK-117 900 mg Tablets | Part-1: TAK-117 900 mg Tablets + TAK-117 900 mg Capsules | Part-2: TAK-117 600 mg Fasted + TAK-117 600 mg Fed | Part-2: TAK-117 600 mg Fed + TAK-117 600 mg Fasted | Part-3: TAK-117 900 mg + Lansoprazole 30 mg | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 6 | 4 | 4 | 4 | 6 | 24 |
| Not Hispanic or Latino | 5 | 5 | 4 | 6 | 10 | 30 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part-1: TAK-117 900 mg Capsules + TAK-117 900 mg Tablets | Part-1: TAK-117 900 mg Tablets + TAK-117 900 mg Capsules | Part-2: TAK-117 600 mg Fasted + TAK-117 600 mg Fed | Part-2: TAK-117 600 mg Fed + TAK-117 600 mg Fasted | Part-3: TAK-117 900 mg + Lansoprazole 30 mg | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 1 | 2 |
| Asian | 1 | 0 | 1 | 0 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 3 | 3 | 3 | 8 | 19 |
| White | 8 | 5 | 4 | 7 | 5 | 29 |
| More than one race | 0 | 0 | 0 | 0 | 2 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Part-1: TAK-117 900 mg Capsules + TAK-117 900 mg Tablets | Part-1: TAK-117 900 mg Tablets + TAK-117 900 mg Capsules | Part-2: TAK-117 600 mg Fasted + TAK-117 600 mg Fed | Part-2: TAK-117 600 mg Fed + TAK-117 600 mg Fasted | Part-3: TAK-117 900 mg + Lansoprazole 30 mg | Total |
|---|---|---|---|---|---|---|
| United States | 11 | 9 | 8 | 10 | 16 | 54 |
No study locations are listed for this record.
Ran from Jan 2016 to primary completion in May 2016, 4 months.
Results were first posted in Jan 2018, 1 year 7 months after primary completion.
Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's 4 months is below that.
Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Serabelisib
Millennium Pharmaceuticals, Inc. →